OR-USB-IF
The USB Promoter Group today announced the release of the USB Power Delivery (USB PD) Revision 3.1 specification, a major update to enable delivering up to 240W of power over the USB Type-C® cable and connector. Prior to this update, USB PD was limited to 100W via a solution based on 20V using USB Type-C cables rated at 5A. The USB Type-C specification has also been updated with Release 2.1 to define 240W cable requirements, and with the updated USB PD protocol and power supply definition, this extends the applicability of USB PD to a large number of applications where 100W wasn’t adequate.
The new USB PD architecture defines a much more stringent power negotiation protocol that helps to ensure that access to and use of this higher power capability can be done safely. It should be noted that safety requirements for products that use power in the range of 100 – 240W are also more stringent than lower power products and are defined by the applicable safety specifications dictated by the regulations for each country where the products will be sold.
“With the new capabilities of USB Power Delivery 3.1, we now enable higher power products such as larger notebook PCs to shift from traditional power connectors to USB Type-C,” said Brad Saunders, USB Promoter Group Chairman. “We also anticipate a wider range of product application developers outside of the traditional USB ecosystem to now consider standardizing on USB Type-C with USB PD power their power needs.”
Key characteristics of the USB PD 3.1 specification include:
- A choice of three new fixed voltages: 28V (above 100W), 36V (above 140W) and 48V (above 180W) joining previously defined 5V, 9V, 15V and 20V fixed voltages.
- A new adjustable voltage mode enabling a range from 15V to one of three maximum voltages (28V, 36V, or 48V) depending on the available power allowing the device being powered to request specific voltages to a 100 mV resolution.
USB Developer Days 2021, in the second half of this year, will include detailed technical training covering the updated USB PD and USB Type-C specifications.
This update is part of the USB performance roadmap and is specifically targeted to developers at this time. Branding and marketing guidelines are being established and will include a new cable labeling solution to inform users of the power capability supported by Certified USB Type-C cables.
“Always responsive to the market’s need for a higher-power, truly universal bus connector, the USB Promoter Group has again been quick to recognize and adapt its specifications for charging capability to anticipate customer requirements, potentially creating new markets for USB Power Delivery. ST, as an active member of the USB Promoter Group, with its strong company legacy of cooperation, technical expertise, and product reliability, will continue to provide high-quality, optimized semiconductor solutions,” said Matteo Lo-Presti, Executive Vice President, Analog, Sub-Group General Manager, Analog MEMS, and Sensors Group, STMicroelectronics.
“The 3.1 revision to the USB Power Delivery specification, which includes the capability to provide up to 48 V and 240 W of power, will help enable additional design opportunities for current and new users of USB Type-C technology,” said Deric Waters, senior member of technical staff at Texas Instruments.
About the USB Promoter Group
The USB Promoter Group, comprised of Apple Inc., Hewlett-Packard Inc., Intel Corporation, Microsoft Corporation, Renesas Electronics Corporation, STMicroelectronics, and Texas Instruments, continues to develop the USB family of specifications to meet the market needs for increased functionality and performance of USB solutions. Additionally, the USB Promoter Group develops specification addendums (USB Power Delivery, USB Type-C®, and others) to extend or adapt its specifications to support more platform types or use cases where adopting USB technology will be beneficial in delivering a more ubiquitous, richer user experience.
About the USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. The USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program, and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at www.usb.org .
USB Type-C® and USB-C® are registered trademarks of USB Implementers Forum.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526006131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom